By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired a minority stake in Alacris Theranostics, a startup using whole-genome sequence analysis to develop individualized cancer therapies.

Qiagen has also acquired a minority stake in EyeSense, a developer of ophthalmic diagnostic systems for glucose monitoring of diabetes patients, EyeSense said in a separate announcement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.